Improvement in a Patient with Active Systemic Lupus Erythematosous Treated with Transplant of Intestinal Microbiota

Tiburcio, Álvaro Zamudio

doi:10.31031/gmr.2019.03.000551

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For humans, an FMT has been performed on one 34-year-old Mexican woman suffering from SLE with glomerulonephritis, weight loss and malnutrition. An improvement has been observed with reduced diarrhoea and anxiety 102…”

Section: Challenges In the Treatment Of Slementioning

confidence: 93%

Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives

et al. 2023

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE is characterised by breaking self-immune tolerance and autoantibody production that triggers inflammation and damage of multiple organs. Given the highly heterogeneous nature of SLE, the treatments currently used are still not satisfactory with considerable side effects, and the development of new therapies is a major health issue for better patient management. In this context, mouse models significantly contribute to our knowledge of the pathogenesis of SLE and are an invaluable tool for testing novel therapeutic targets. Here, we discuss the role of the most used SLE mouse models and their contribution to therapeutic improvement. Considering the complexity of developing targeted therapies for SLE, adjuvant therapies are also increasingly proposed. Indeed, murine and human studies have recently revealed that gut microbiota is a potential target and holds great promises for successful new SLE therapies. However, the mechanisms of gut microbiota dysbiosis in SLE remain unclear to date. In this review, we propose an inventory of existing studies investigating the relationship between gut microbiota dysbiosis and SLE to establish microbiome signature that may serve as a potential biomarker of the disease and its severity as well as a new potential therapy target. This approach may open new possibilities for early diagnosis, prevention and therapeutic perspectives of SLE based on gut microbiome.

show abstract

Section: Challenges In the Treatment Of Slementioning

confidence: 93%

Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The study also showed that untreated mice could be transplanted with the fecal microbiota of prednisone-treated mice without fear of side effects [127] . Clinical trials of FMT have already been conducted in patients with other autoimmune diseases, such as type 1 diabetes and ulcerative colitis, with some success [128][129] . FMT was applied to a patient with SLE who was infected with a Blastocystis hominis parasite and who also had glomerulonephritis, malnutrition, diarrhea, and severe weight loss; after FMT treatment, there was an improvement in diarrhea and anxiety [130] .…”

Section: Gut Microbiota Therapeutic Approachesmentioning

confidence: 99%

Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation

Chasov,

Zmievskaya,

Ganeeva

et al. 2024

J Biomed Res

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is characterized by a systemic dysfunction of the innate and adaptive immune systems, leading to an attack on healthy tissues of the body. During the development of SLE, pathogenic features, such as the formation of autoantibodies to self-nuclear antigens, caused tissue damage including necrosis and fibrosis, with an increased expression of type Ⅰ interferon (IFN) regulated genes. Treatment of lupus with immunosuppressants and glucocorticoids, which are used as the standard therapy, is not effective enough and causes side effects. As an alternative, more effective immunotherapies have been developed, including monoclonal and bispecific antibodies that target B cells, T cells, co-stimulatory molecules, cytokines or their receptors, and signaling molecules. Encouraging results have been observed in clinical trials with some of these therapies. Furthermore, a chimeric antigen receptor T cells (CAR-T) therapy has emerged as the most effective, safe, and promising treatment option for SLE, as demonstrated by successful pilot studies. Additionally, emerging evidence suggests that gut microbiota dysbiosis may play a significant role in the severity of SLE, and the use of methods to normalize the gut microbiota, particularly fecal microbiota transplantation (FMT), opens up new opportunities for effective treatment of SLE.

show abstract

Improvement in a Patient with Active Systemic Lupus Erythematosous Treated with Transplant of Intestinal Microbiota

Cited by 2 publications

References 33 publications

Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives

Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives

Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation

Contact Info

Product

Resources

About